Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
暂无分享,去创建一个
J. Blay | J. Dopazo | A. Italiano | A. D. Dei Tos | E. de Álava | P. Casali | J. Martín-Broto | S. Stacchiotti | M. Peña-Chilet | M. Tarón | D. Ranchère‐Vince | G. Grignani | M. Biscuola | P. Collini | S. Dumont | E. Palmerini | A. Redondo | A. Lecesne | D. Moura | N. Hindi | J. Díaz-Martín | A. López-pousa | A. Gutiérrez | X. García del Muro | J. Cruz | J. Martínez-Trufero | A. Sebio | D. Bernabeu
[1] B. Kerns,et al. Developmental profiling of microRNAs in the human embryonic inner ear , 2018, PloS one.
[2] Wei-Lien Wang,et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model , 2017, Modern Pathology.
[3] A. D. Dei Tos,et al. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. , 2017, European journal of cancer.
[4] A. Shinagare,et al. Metastatic Patterns of Solitary Fibrous Tumors: A Single-Institution Experience. , 2017, AJR. American journal of roentgenology.
[5] Michael P. Snyder,et al. Abstract 3616: Fix the fixation: effect of formalin fixation on targeted sequencing, variant calling and gene expression , 2016 .
[6] M. Zeng,et al. ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma , 2016, Oncotarget.
[7] Robin L. Jones,et al. The Current Status of Solitary Fibrous Tumor , 2016, International journal of surgical pathology.
[8] V. Sondak,et al. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience , 2015, PloS one.
[9] F. Bertucci,et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. , 2015, European journal of cancer.
[10] I. Judson,et al. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience , 2015, Clinical Sarcoma Research.
[11] A. D. Dei Tos,et al. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. , 2014, European journal of cancer.
[12] F. Mertens,et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics , 2014, Modern Pathology.
[13] G. Ball,et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] O. Larsson,et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor , 2013, Genes, chromosomes & cancer.
[15] F. Coevorden,et al. Prognosis of Solitary Fibrous Tumors: A Multicenter Study , 2013, Annals of Surgical Oncology.
[16] L. Mariani,et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. , 2013, European journal of cancer.
[17] Wei-Lien Wang,et al. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis , 2013, Clinical Sarcoma Research.
[18] P. O'dwyer,et al. Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy , 2013, Clinical Cancer Research.
[19] K. Pienta,et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.
[20] Daniel Auclair,et al. Whole exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors , 2013, Nature Genetics.
[21] C. Fletcher,et al. WHO classification of tumours of soft tissue and bone , 2013 .
[22] A. D. Dei Tos,et al. Sunitinib malate in solitary fibrous tumor (SFT). , 2012 .
[23] P. Fox,et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model , 2012, Modern Pathology.
[24] U. Pastorino,et al. High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors: A Clinicopathologic Study of 10 Cases , 2012, The American journal of surgical pathology.
[25] A. Lazar,et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor , 2011, Cancer.
[26] J. Mosquera,et al. Expanding the Spectrum of Malignant Progression in Solitary Fibrous Tumors: A Study of 8 Cases With a Discrete Anaplastic Component—Is This Dedifferentiated SFT? , 2009, The American journal of surgical pathology.
[27] Peter A Fasching,et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer , 2008, Breast Cancer Research.
[28] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Dry,et al. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. , 1998, The American journal of surgical pathology.
[30] L. Hochholzer,et al. Localized Benign and Malignant Fibrous Tumors of the Pleura: A Clinicopathologic Review of 223 Cases , 1989, The American journal of surgical pathology.